Docket No.: 638772000301
`
`(PATENT)
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`In re Patent Application of:
`Neil P. DESAI et al.
`
`Application No.: 11/553,339
`
`Confirmation No.: 3605
`
`Filed: October 26, 2006
`
`Art Unit: 1656
`
`For: COMPOSITIONS AND METHODS OF
`DELIVERY OF PHARMACOLOGICAL
`
`Examiner: M. Tsay
`
`AGENTS
`
`AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION
`
`MS Amendment
`
`Commissioner for Patents
`
`PO. Box 1450
`
`Alexandria, VA 22313— 1450
`
`Dear Sir:
`
`INTRODUCTORY COMMENTS
`
`This is in response to the non—final Office Action dated April 28, 2009 (Paper No.
`
`20090415), for which a response was due on July 28, 2009. Filed herewith is a Petition and fee for
`
`a three month(s) extension of time, thereby extending the deadline for response to October 28, 2009.
`
`Accordingly, this response is timely filed. Reconsideration and allowance of the pending claims, as
`
`amended, in light of the remarks presented herein are respectfully requested.
`
`Amendments to the Claims are reflected in the listing of claims which begins on page 2
`
`of this paper.
`
`Remarks/Arguments begin on page 5 of this paper.
`
`pa-1336926
`
`Actavis - IPR2017-O1104, Ex. 1020, p. 1 of 10
`
`Actavis - IPR2017-01104, Ex. 1020, p. 1 of 10
`
`

`

`Application No.: 11/553,339
`
`2
`
`Docket No.: 638772000301
`
`AMENDMENTS TO THE CLAIMS
`
`This listing of claims will replace all prior versions, and listings, of
`
`claims in the application:
`
`Claim 1 (Cancelled)
`
`Claim 2 (Currently amended): A pharmaceutical composition comprising a pharmaceutical agent
`
`and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier
`
`comprises albumin, wherein the albumin and the pharmaceutical agent in the composition are
`
`formulated as nanoparticles, and wherein the weight ratio of albumin to pharmaceutical agent in the
`
`composition is about 1:1 to about §:—1—
`
`Claim 3 (Previously presented): The pharmaceutical composition of claim 2, wherein the
`
`nanoparticles have a mean—diameter of less than about 200 nm.
`
`Claim 4 (Previously presented): The pharmaceutical composition of claim 2, wherein the albumin
`
`is human serum albumin.
`
`Claim 5 (Previously presented): The pharmaceutical composition of claim 2, wherein the
`
`pharmaceutical agent is selected from the group consisting of anticancer agents, anesthetics,
`
`antimicrotubule agents, agents to treat cardiovascular disorders, antihypertensives, anti—
`
`inflammatory agents, anti—arthritic agents, antiasthmatics, analgesics, vasoactive agents,
`
`immunosuppressive agents, antifungal agents, antiarrhythmic agents, antibiotics, and hormones.
`
`Claim 6 (Previously presented): The pharmaceutical composition of claim 5, wherein the
`
`pharmaceutical agent is an anticancer agent.
`
`Claim 7 (Withdrawn): The pharmaceutical composition of claim 5, wherein the pharmaceutical
`
`agent is an anti—inflammatory agent.
`
`Claim 8 (Withdrawn): The pharmaceutical composition of claim 5, wherein the pharmaceutical
`
`agent is an immunosuppressive agent.
`
`pa-1336926
`
`Actavis - IPR2017-O1104, Ex. 1020, p. 2 of 10
`
`Actavis - IPR2017-01104, Ex. 1020, p. 2 of 10
`
`

`

`Application No.: 11/553,339
`
`3
`
`Docket No.: 638772000301
`
`Claim 9 (Withdrawn): The pharmaceutical composition of claim 5, wherein the pharmaceutical
`
`agent is an antibiotic.
`
`Claim 10 (Previously presented): The pharmaceutical composition of claim 2, wherein the
`
`pharmaceutical agent is selected from the group consisting of paclitaxel, docetaxel, taxanes,
`
`camptothecin, propofol, amiodarone, cyclosporine, rapamycin, amphotericin, liothyronine,
`
`epothilones, colchicines, thyroid hormones, vasoactive intestinal peptide, corticosteroids,
`
`melatonin, tacrolimus, mycophenolic acids.
`
`Claim 11 (Previously presented): The pharmaceutical composition of claim 10, wherein the
`
`anticancer agent is a taxane.
`
`Claim 12 (Previously presented): The pharmaceutical composition of claim 11, wherein the
`
`pharmaceutical_agent is paclitaxel.
`
`Claim 13 (Previously presented): The pharmaceutical composition of claim 12, wherein the
`
`pharmaceutical composition is free of Cremophor.
`
`Claim 14 (Withdrawn): A method of treating a disease comprising administering an effective
`
`amount of a pharmaceutical composition of claim 2.
`
`Claim 15 (Withdrawn): The method of claim 14, wherein the disease is cancer.
`
`Claim 16 (Withdrawn): The method of claim 14, wherein the disease is arthritis.
`
`Claim 17 (Withdrawn): The method of claim 14, wherein the disease is cardiovascular disease.
`
`Claim 18 (Withdrawn): The method of claim 17, wherein the disease is restenosis.
`
`Claim 19 (Withdrawn): The method of claim 14, wherein the composition is administered
`
`intravenously, intraarterially, intrapulmonary, orally, by inhalation, intravasicularly,
`
`intramuscularly, intra—tracheally, subcutaneously, intraocularly, intrathecally, or transdermally.
`
`pa-1336926
`
`Actavis - IPR2017-O1104, Ex. 1020, p. 3 of 10
`
`Actavis - IPR2017-01104, Ex. 1020, p. 3 of 10
`
`

`

`Application No.: 11/553,339
`
`4
`
`Docket No.: 638772000301
`
`Claim 20 (Withdrawn): The method of claim 19, wherein the pharmaceutical composition is
`
`administered intravenously.
`
`Claim 21 (Withdrawn): The method of claim 19, wherein the pharmaceutical composition is
`
`administered orally.
`
`Claim 22 (Withdrawn and Currently Amended): A method of preparing a pharmaceutical
`
`composition of claim 2, comprising combining a pharmaceutical agent with a pharmaceutically
`
`acceptable carrier comprising albumin, wherein the weight ratio of albumin to the pharmaceutical
`
`agent in the composition is aboutéfl—or—less about 1:1 to about 9:1.
`
`Claim 23 (Withdrawn): The method of claim 22, further comprising subjecting the combination of
`
`the pharmaceutical agent and the pharmaceutically acceptable carrier to high pressure
`
`homogenization.
`
`Claim 24 (New): The pharmaceutical composition of claim 2, wherein the ratio (w/w) of albumin to
`
`the pharmaceutical agent in the pharmaceutical composition is about 1:1 to about 5:1.
`
`Claim 25 (New): The pharmaceutical composition of claim 2, wherein the ratio (w/w) of albumin to
`
`the pharmaceutical agent in the pharmaceutical composition is 1:1 to 9:1.
`
`Actavis - IPR201 7-01 1
`
`pa-1336926
`
`Actavis - IPR2017-01104, Ex. 1020, p. 4 of 10
`
`

`

`Application No.: 11/553,339
`
`5
`
`Docket No.: 638772000301
`
`REMARKS
`
`Claims 2—23 are pending in the present application. Claims 7—9 and 14—23 are withdrawn
`
`from consideration. By this amendment, pending claims 2 and withdrawn claim 22 are amended.
`
`New claims 24 and 25 are added. Upon entry of this amendment, claims 2—6, 10—13, and 24—25 are
`
`under examination.
`
`Support for the amendment of claim 2 and 22 can be found at page 14, line 21 (Paragraph
`
`[0041]) of the specification.
`
`With respect to claim amendments and cancellation, Applicants have not dedicated or
`
`abandoned any unclaimed subject matter and moreover have not acquiesced to any rejections and/or
`
`objections made by the Patent Office. Applicants expressly reserve the right to pursue prosecution
`
`of any presently excluded subject matter or claim embodiments in one or more future continuation
`
`and/or divisional application(s).
`
`Summary of interview
`
`Applicants express their gratitude for the telephonic interview between Examiner Marsha M.
`
`Tsay and Applicants’ representative Jian (Janet) Xiao on May 19, 2009. The time and consideration
`
`of the Examiner is greatly appreciated.
`
`During the May 19, 2009 interview, the Examiner and Applicants’ representatives briefly
`
`discussed the 35 U.S.C. § 103(a) rejection cited in the Office Action. Applicants inquired about the
`
`possibility of amending the independent claim to recite a ratio of “about 1:1 to about 9:1.” The
`
`Examiner indicated that such amended claim will be examined.
`
`Rejection under 35 U.S.C. § 103(a)
`
`Claims 2—6 and 10—13 are rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable
`
`over Damascelli et al. (“Damascelli,” 2001 Cancer 92(10): 2592—2602) in view of Ibrahim et al.
`
`(“Ibrahim,” 2000 Proc Am Soc Clin Onco 19: abstract 609F). Applicants respectfully traverse this
`
`rejection. The response addresses claims as amended, and the arguments presented herein apply
`
`equally to the claims prior to the amendment.
`
`pa-1336926
`
`Actavis - IPR2017-O1104, Ex. 1020, p. 5 of 10
`
`Actavis - IPR2017-01104, Ex. 1020, p. 5 of 10
`
`

`

`Application No.: 11/553,339
`
`6
`
`Docket No.: 638772000301
`
`The claims as amended are directed to “a pharmaceutical composition comprising a
`
`pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically
`
`acceptable carrier comprises albumin, wherein the albumin and the pharmaceutical agent in the
`
`composition are formulated as nanoparticles, and wherein the weight ratio of albumin to
`
`pharmaceutical agent in the composition is about 1:1 to about 9:1.” The present application teaches
`
`that a low albumin/pharmaceutical agent ratio, such as the ratios recited in the claims of the present
`
`application, allows enhanced cellular binding and transport of the pharmaceutical agent. As stated
`
`in paragraph [0041] of the present application,
`
`Not to adhere to any one particular theory, it is believed that the ratio of protein, e. g., human
`serum albumin, to pharmaceutical agent in the pharmaceutical composition affects the
`ability of the pharmaceutical agent to bind and transport the pharmaceutical agent to a cell.
`In this regard, higher ratios of protein to pharmaceutical agent generally are associated with
`poor cell binding and transport of the pharmaceutical agent, which possibly is the result of
`competition for receptors at the cell surface. The ratio of protein, e. g., albumin, to active
`pharmaceutical agent must be such that a sufficient amount of pharmaceutical agent binds
`to, or is transported by, the cell.
`
`Example 45 demonstrates that increasing amounts of albumin can compete with the binding
`
`of a pharmaceutical agent, namely, paclitaxel, to the cell surface, and states that “higher albumin
`
`concentration inhibited binding of paclitaxel. Thus, invention compositions having lower amounts
`
`of albumin are preferred.”
`
`The present application further teaches that a low albumin/pharmaceutical agent ratio, such
`
`as the ratios recited in claims of the present application, allows formation of stable nanoparticle
`
`compositions of the pharmaceutical agent. Specifically, Example 46 states,
`
`To investigate if lower amounts of albumin in the composition would affect stability of the
`inventive pharmaceutical composition, albumin—paclitaxel compositions with low amounts
`of albumin were prepared. It was found that these compositions were as stable as
`compositions with higher quantities of albumin when examined for several months at
`different temperatures (2—8 °C, 25 °C, and 40 °C) for potency of paclitaxel, impurity
`formation, particle size, pH and other typical parameters of stability. Thus compositions
`with lower amounts of albumin are preferred as this can greatly reduce cost as well as allow
`increased binding and transport to cells.
`
`pa-1336926
`
`Actavis - IPR2017-O1104, Ex. 1020, p. 6 of 10
`
`Actavis - IPR2017-01104, Ex. 1020, p. 6 of 10
`
`

`

`Application No.: 11/553,339
`
`7
`
`Docket No.: 638772000301
`
`Example 48 further demonstrates the production of a nanoparticle pharmaceutical
`
`composition with a starting albumin/paclitaxel ratio of 4.5:1.
`
`Thus, a low albumin/pharmaceutical agent ratio, such as the ratios recited in claims of the
`
`present application, allows enhanced cellular binding and transport of the pharmaceutical agent
`
`while at the same time allowing the formation of stable nanoparticle compositions of the
`
`pharmaceutical agent even at the low ratio. Such advantageous result and characteristics were
`
`neither taught nor suggested in the cited references.
`
`The two references cited by the Examiner, namely, Damascelli and Ibrahim, are silent about
`
`the weight ratio of albumin to pharmaceutical agent in the compositions disclosed therein. They
`
`neither teach nor suggest the significance of the albumin/pharmaceutical agent ratio on cellular
`
`binding and transport. Nor do they teach or suggest that a low albumin/pharmaceutical agent ratio,
`
`such as those recited in the claims of the present application, would allow enhanced cellular binding
`
`and transport of the pharmaceutical agent while at the same time allowing the formation of stable
`
`nanoparticle compositions of the pharmaceutical agent even at low ratio.
`
`The Examiner acknowledges that Damascelli does not disclose a specific albumin/paclitaxel
`
`ratio, but states that “it would have been obvious to one of ordinary skill in the art at the time the
`
`invention was made to modify the teachings of Damascelli by determining the optimum
`
`concentration and/or weight ratio of albumin to paclitaxel that will result in a composition that will
`
`deliver paclitaxel most effectively in an albumin delivery system.” Applicants respectfully
`
`disagree.
`
`First, Damascelli is completely silent about any need or even desirability to further modify
`
`the composition disclosed therein in order to delivery paclitaxel more effectively. According to
`
`Damascelli, intraarterial administration of AB1007 has “acceptable toxicity” and at most dose levels
`
`“showed considerable antitumor activity (42 assessable patients with 80.9% complete response and
`
`partial response).” See Abstract. There is no indication that delivery of paclitaxel needs to or
`
`should be further improved.
`
`pa-1336926
`
`Actavis - IPR2017-O1104, Ex. 1020, p. 7 of 10
`
`Actavis - IPR2017-01104, Ex. 1020, p. 7 of 10
`
`

`

`Application No.: 11/553,339
`
`8
`
`Docket No.: 638772000301
`
`Second, Damascelli provides no direction or basis for adjusting the weight ratio of albumin
`
`to paclitaxel in the composition disclosed therein for the purpose of improving the composition, let
`
`alone any direction or basis for choosing a low albumin/pharmaceutical agent ratio, such as the
`
`ratios recited in the present application.
`
`MPEP states,
`
`B. Only Result-Effective Variables Can be Optimized
`
`A particular parameter must first be recognized as a result—effective variable, i.e., a variable
`which achieves a recognized result, before the determination of the optimum or workable
`range of said variable might be characterized as routine experimentation. In re Antonie, 559
`F.2d 618, 195 USPQ 6 (CCPA 1977)(The claimed waste water treatment device had a tank
`
`volume to contractor area of 0.12 gal/sq. ft. The prior art did not recognize that treatment
`capacity is a function of the tank volume to contractor ratio, and therefore the parameter
`optimized was not recognized in the art to be a result—effective variable.). See also in re
`Boesch, 617 F.2d 272, 205 (CCPA 1980) (prior art suggested proportional balancing to
`achieve desired results in the formation of an alloy).
`
`MPEP §2144.05.II.B.
`
`As discussed above, Damascelli is silent about weight ratio of albumin to pharmaceutical
`
`agent, namely, paclitaxel, in the composition disclosed therein. Nor does Damascelli teach or
`
`suggest the significance of the albumin/pharmaceutical agent ratio on cellular binding and transport.
`
`Without a recognition in the art of the significance of albumin/pharmaceutical agent ratio, for
`
`example in cellular binding and transport of the pharmaceutical agent, one of ordinary skill would
`
`not have been motivated to adjust the albumin/pharmaceutical agent ratio, let alone to choose a low
`
`albumin/pharmaceutical agent ratio, such as the ratios recited in the present application, in order to
`
`make a composition that will delivery the pharmaceutical agent most effectively in an albumin
`
`delivery system.
`
`Similarly, Ibrahim neither discloses a weight ratio of albumin to pharmaceutical agent nor
`
`teaches the significance of the albumin/pharmaceutical agent ratio on the cellular binding and
`
`transport.
`
`pa-1336926
`
`Actavis - IPR2017-O1104, Ex. 1020, p. 8 of 10
`
`Actavis - IPR2017-01104, Ex. 1020, p. 8 of 10
`
`

`

`Application No.: 11/553,339
`
`9
`
`Docket No.: 638772000301
`
`Because it has not been established that the weight ratio of albumin to pharmaceutical agent
`
`was recognized in the art as a result—effective variable, Applicants respectfully submit that the
`
`rejection of the claims should be withdrawn.
`
`Applicants further respectfully submit that optimization and/or achieving a desired result do
`
`not mean the result is non—inventive. As discussed above, the albumin/pharmaceutical agent ratios
`
`recited in claims of the present application allow enhanced cellular binding and transport of the
`
`pharmaceutical agent while at the same time allowing the formation of stable nanoparticle
`
`compositions of the pharmaceutical agent even at the low ratio. Such advantageous result and
`
`characteristics were neither predictable based on the teaching of the cited references nor expected by
`
`a person of ordinary skill in the art.
`
`Accordingly, Applicants respectfully request that the rejection under 35 U.S.C. §103(a) be
`
`withdrawn.
`
`Actavis - IPR201 7-01 1
`
`pa-1336926
`
`Actavis - IPR2017-01104, Ex. 1020, p. 9 of 10
`
`

`

`Application No.: 11/553,339
`
`10
`
`Docket No.: 638772000301
`
`CONCLUSION
`
`In view of the above, each of the presently pending claims in this application is believed
`
`to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to
`
`withdraw the outstanding rejection of the claims and to pass this application to issue. If it is
`
`determined that a telephone conference would expedite the prosecution of this application, the
`
`Examiner is invited to telephone the undersigned at the number given below.
`
`In the event the U.S. Patent and Trademark office determines that an extension and/or
`
`other relief is required, applicant petitions for any required relief including extensions of time and
`
`authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection
`
`with the filing of this document to Deposit Account No. 03—1952 referencing docket no.
`
`638772000301. However, the Commissioner is not authorized to charge the cost of the issue fee to
`
`the Deposit Account.
`
`Dated: October 27, 2009
`
`Respectfully submitted,
`
`Electronic Signature:
`Jian Xiao
`
`/Jian Xiao/
`
`Registration No.: 55,748
`MORRISON & FOERSTER LLP
`
`755 Page Mill Road
`Palo Alto, California 94304—1018
`
`(650) 813—5736
`
`Actavis - IPR201 7-01 1
`
`pa-1336926
`
`Actavis - IPR2017-01104, Ex. 1020, p. 10 of 10
`
`